{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:11:52Z","timestamp":1707523912683},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,21]]},"DOI":"10.7759\/cureus.49198","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:39:53Z","timestamp":1700606393000},"source":"Crossref","is-referenced-by-count":0,"title":["Complete Response to Cetuximab Plus Paclitaxel Therapy in Nivolumab-Refractory Patients in Distant Metastasis of Squamous Cell Carcinoma of the Tongue: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Hidetake","family":"Tachinami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Tomihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danki","family":"Takatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris RL","year":"2018","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al.. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018, 81:45-51. 10.1016\/j.oraloncology.2018.04.008","journal-title":"Oral Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman G","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G, et al.. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017, 112:90-5. 10.1016\/j.lungcan.2017.07.034","journal-title":"Lung Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park SE","year":"2018","unstructured":"Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol. 2018, 13:106-11. 10.1016\/j.jtho.2017.10.011","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.04.013","article-title":"Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy","volume":"81","author":"Daste A","year":"2018","unstructured":"Daste A, De-Mones E, Cochin V, Dupin C, Digue L, Ravaud A, Domblides C. Progression beyond nivolumab: stop or repeat? Dramatic responses with salvage chemotherapy. Oral Oncol. 2018, 81:116-8. 10.1016\/j.oraloncology.2018.04.013","journal-title":"Oral Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12543","article-title":"Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy","volume":"9","author":"Ogawara D","year":"2018","unstructured":"Ogawara D, Soda H, Iwasaki K, Suyama T, Taniguchi H, Fukuda Y, Mukae H. Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. Thorac Cancer. 2018, 9:175-80. 10.1111\/1759-7714.12543","journal-title":"Thorac Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen DS","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013, 39:1-10. 10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2014.01.013","article-title":"Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer","volume":"50","author":"Tomihara K","year":"2014","unstructured":"Tomihara K, Fuse H, Heshiki W, et al.. Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. Oral Oncol. 2014, 50:457-67. 10.1016\/j.oraloncology.2014.01.013","journal-title":"Oral Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6015","article-title":"Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck","volume":"36","author":"Saleh K","year":"2018","unstructured":"Saleh K, Daste A, Martin N, et al.. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2018, 36:6015. 10.1200\/JCO.2018.36.15_suppl.6015","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study","author":"Burtness B","year":"2019394","unstructured":"Burtness B, Harrington KJ, Greil R, et al.. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomised, open-label, phase 3 study. Lancet. 2019394, 1915-28. 10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183726-complete-response-to-cetuximab-plus-paclitaxel-therapy-in-nivolumab-refractory-patients-in-distant-metastasis-of-squamous-cell-carcinoma-of-the-tongue-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:40Z","timestamp":1707508480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183726-complete-response-to-cetuximab-plus-paclitaxel-therapy-in-nivolumab-refractory-patients-in-distant-metastasis-of-squamous-cell-carcinoma-of-the-tongue-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.49198","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}